University of Hertfordshire

From the same journal

Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples

Research output: Contribution to journalArticlepeer-review

Standard

Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples. / Kazarian, Anna; Blyuss, Oleg; Metodieva, Gergana; Gentry-Maharaj, Aleksandra; Ryan, Andy; Kiseleva, Elena M; Prytomanova, Olga M; Jacobs, Ian J; Widschwendter, Martin; Menon, Usha; Timms, John F.

In: British Journal of Cancer, Vol. 116, No. 4, 14.02.2017, p. 501-508.

Research output: Contribution to journalArticlepeer-review

Harvard

Kazarian, A, Blyuss, O, Metodieva, G, Gentry-Maharaj, A, Ryan, A, Kiseleva, EM, Prytomanova, OM, Jacobs, IJ, Widschwendter, M, Menon, U & Timms, JF 2017, 'Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples', British Journal of Cancer, vol. 116, no. 4, pp. 501-508. https://doi.org/10.1038/bjc.2016.433

APA

Kazarian, A., Blyuss, O., Metodieva, G., Gentry-Maharaj, A., Ryan, A., Kiseleva, E. M., Prytomanova, O. M., Jacobs, I. J., Widschwendter, M., Menon, U., & Timms, J. F. (2017). Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples. British Journal of Cancer, 116(4), 501-508. https://doi.org/10.1038/bjc.2016.433

Vancouver

Kazarian A, Blyuss O, Metodieva G, Gentry-Maharaj A, Ryan A, Kiseleva EM et al. Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples. British Journal of Cancer. 2017 Feb 14;116(4):501-508. https://doi.org/10.1038/bjc.2016.433

Author

Kazarian, Anna ; Blyuss, Oleg ; Metodieva, Gergana ; Gentry-Maharaj, Aleksandra ; Ryan, Andy ; Kiseleva, Elena M ; Prytomanova, Olga M ; Jacobs, Ian J ; Widschwendter, Martin ; Menon, Usha ; Timms, John F. / Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples. In: British Journal of Cancer. 2017 ; Vol. 116, No. 4. pp. 501-508.

Bibtex

@article{cf08efd2d59b4c32a056c72ad7c37edd,
title = "Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples",
abstract = "BACKGROUND: Breast cancer is a leading cause of morbidity and mortality worldwide. Although mammography screening is available, there is an ongoing interest in improved early detection and prognosis. Herein, we have analysed a combination of serological biomarkers in a case-control cohort of sera taken before diagnosis.METHODS: This nested case-control study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) used serum samples from 239 women who subsequently developed breast cancer and 239 matched cancer-free controls. Sera were screened by ELISA for 9 candidate markers. Univariate and multivariate analyses were performed to examine associations with clinico-pathological features and between case controls in different time groups before diagnosis.RESULTS: Significant associations with clinico-pathological features related to prognosis were found for several candidates (CA15-3, HSP90A and PAI-1). However, there were no consistent differences between cases and controls for any candidate in the lead up to diagnosis. Whilst combination models outperformed single markers, there was no increase in performance towards diagnosis.CONCLUSIONS: This study using unique pre-diagnosis samples shows that CA15-3, HSP90A and PAI-1 have potential as early prognostic markers and warrant further investigation. However, none of the candidates or combinations would be useful for screening.",
keywords = "Aged, Biomarkers, Tumor/blood, Breast Neoplasms/blood, Case-Control Studies, Early Detection of Cancer/methods, Enzyme-Linked Immunosorbent Assay, Female, Humans, Mass Screening/methods, Middle Aged, Prognosis, United Kingdom",
author = "Anna Kazarian and Oleg Blyuss and Gergana Metodieva and Aleksandra Gentry-Maharaj and Andy Ryan and Kiseleva, {Elena M} and Prytomanova, {Olga M} and Jacobs, {Ian J} and Martin Widschwendter and Usha Menon and Timms, {John F}",
year = "2017",
month = feb,
day = "14",
doi = "10.1038/bjc.2016.433",
language = "English",
volume = "116",
pages = "501--508",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "4",

}

RIS

TY - JOUR

T1 - Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples

AU - Kazarian, Anna

AU - Blyuss, Oleg

AU - Metodieva, Gergana

AU - Gentry-Maharaj, Aleksandra

AU - Ryan, Andy

AU - Kiseleva, Elena M

AU - Prytomanova, Olga M

AU - Jacobs, Ian J

AU - Widschwendter, Martin

AU - Menon, Usha

AU - Timms, John F

PY - 2017/2/14

Y1 - 2017/2/14

N2 - BACKGROUND: Breast cancer is a leading cause of morbidity and mortality worldwide. Although mammography screening is available, there is an ongoing interest in improved early detection and prognosis. Herein, we have analysed a combination of serological biomarkers in a case-control cohort of sera taken before diagnosis.METHODS: This nested case-control study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) used serum samples from 239 women who subsequently developed breast cancer and 239 matched cancer-free controls. Sera were screened by ELISA for 9 candidate markers. Univariate and multivariate analyses were performed to examine associations with clinico-pathological features and between case controls in different time groups before diagnosis.RESULTS: Significant associations with clinico-pathological features related to prognosis were found for several candidates (CA15-3, HSP90A and PAI-1). However, there were no consistent differences between cases and controls for any candidate in the lead up to diagnosis. Whilst combination models outperformed single markers, there was no increase in performance towards diagnosis.CONCLUSIONS: This study using unique pre-diagnosis samples shows that CA15-3, HSP90A and PAI-1 have potential as early prognostic markers and warrant further investigation. However, none of the candidates or combinations would be useful for screening.

AB - BACKGROUND: Breast cancer is a leading cause of morbidity and mortality worldwide. Although mammography screening is available, there is an ongoing interest in improved early detection and prognosis. Herein, we have analysed a combination of serological biomarkers in a case-control cohort of sera taken before diagnosis.METHODS: This nested case-control study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) used serum samples from 239 women who subsequently developed breast cancer and 239 matched cancer-free controls. Sera were screened by ELISA for 9 candidate markers. Univariate and multivariate analyses were performed to examine associations with clinico-pathological features and between case controls in different time groups before diagnosis.RESULTS: Significant associations with clinico-pathological features related to prognosis were found for several candidates (CA15-3, HSP90A and PAI-1). However, there were no consistent differences between cases and controls for any candidate in the lead up to diagnosis. Whilst combination models outperformed single markers, there was no increase in performance towards diagnosis.CONCLUSIONS: This study using unique pre-diagnosis samples shows that CA15-3, HSP90A and PAI-1 have potential as early prognostic markers and warrant further investigation. However, none of the candidates or combinations would be useful for screening.

KW - Aged

KW - Biomarkers, Tumor/blood

KW - Breast Neoplasms/blood

KW - Case-Control Studies

KW - Early Detection of Cancer/methods

KW - Enzyme-Linked Immunosorbent Assay

KW - Female

KW - Humans

KW - Mass Screening/methods

KW - Middle Aged

KW - Prognosis

KW - United Kingdom

U2 - 10.1038/bjc.2016.433

DO - 10.1038/bjc.2016.433

M3 - Article

C2 - 28081538

VL - 116

SP - 501

EP - 508

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 4

ER -